Royalty Pharma Plc (RPRX)
61.33
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
61.32
-0.01
(-0.02%)
After-Hours: 20:00
Royalty Pharma Profit Margin (Quarterly) : 12.09% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.09% |
| March 31, 2026 | 74.26% |
| December 31, 2025 | 57.23% |
| September 30, 2025 | 72.91% |
| June 30, 2025 | 16.01% |
| March 31, 2025 | 76.45% |
| December 31, 2024 | 56.23% |
| September 30, 2024 | |
| June 30, 2024 | 36.18% |
| March 31, 2024 | -0.75% |
| December 31, 2023 | |
| September 30, 2023 | 22.76% |
| June 30, 2023 | 65.28% |
| March 31, 2023 | 74.43% |
| December 31, 2022 | -107.8% |
| Date | Value |
|---|---|
| September 30, 2022 | 38.44% |
| June 30, 2022 | 91.72% |
| March 31, 2022 | 22.79% |
| December 31, 2021 | 9.38% |
| September 30, 2021 | 37.86% |
| June 30, 2021 | |
| March 31, 2021 | 27.74% |
| December 31, 2020 | 64.16% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 21.78% |
| December 31, 2019 | |
| September 30, 2019 | 94.78% |
| June 30, 2019 | 39.07% |
| March 31, 2019 | 91.08% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| AstraZeneca PLC | 20.15% |
| Johnson & Johnson | 21.86% |
| Viatris, Inc. | -3.16% |
| ANI Pharmaceuticals, Inc. | 8.65% |
| Corcept Therapeutics, Inc. | 16.45% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 13.90% |
| Return on Assets | 6.96% |
| Return on Invested Capital | 7.30% |
| Gross Profit Margin (Quarterly) | 99.81% |
| Operating Margin (Quarterly) | 19.75% |
| Return on Net Operating Assets | 7.60% |